06/04/2026 Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 Amgen announced topline results from Phase 3 teprotumumab in active TED Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 ( Ref ) Tenvie Therapeutics announced the first subject dosed in a Phase 1 clinical study evaluating TNV262 (a fully CNS-penetrant small molecule inhibitor targeting NLRP3) for the treatment of cardiometabolic diseases, including obesi

26/02/2026 GSK’s linerixibat accepted for Priority review by China’s NMPA in patients with PBC Boehringer acquired an exclusive license for a novel oral therapeutics program for immune diseases from Sitryx Argenx announced topline results from Phase 3 trial of VYVGART in Ocular myasthenia gravis Soligenix received a positive opinion from the EMA on its request for orphan drug designation for SGX945 for the treatment of behçet's disease GSK’s linerixibat accepted for Priority